(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics, Inc. (STOK) Tuesday announced partnership to develop and sell zorevunersen, Stoke's drug candidate for the treatment of Dravet syndrome, in all ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in ...

In recent days, Biogen and its partners announced the FDA approval and October launch of LEQEMBI Iqlik, a subcutaneous, at-home formulation for early Alzheimer's disease, along with new positive ...

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease ...

– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard ...

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) ...

– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Biogen Inc. stands sixth on our list among the most undervalued stocks. Biogen Inc. (NASDAQ:BIIB) is a global biotechnology leader ...

Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific ...